Onconova Therapeutics Operating Margin vs. Cash Per Share

ONTXDelisted Stock  USD 1.02  0.04  3.77%   
Based on Onconova Therapeutics' profitability indicators, Onconova Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Onconova Therapeutics' ability to earn profits and add value for shareholders.
For Onconova Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Onconova Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Onconova Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Onconova Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Onconova Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Please note, there is a significant difference between Onconova Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconova Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconova Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Onconova Therapeutics Cash Per Share vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Onconova Therapeutics's current stock value. Our valuation model uses many indicators to compare Onconova Therapeutics value to that of its competitors to determine the firm's financial worth.
Onconova Therapeutics is rated below average in operating margin category among its peers. It is rated below average in cash per share category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Onconova Therapeutics' earnings, one of the primary drivers of an investment's value.

Onconova Cash Per Share vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Onconova Therapeutics

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
(89.28) %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Onconova Therapeutics

Cash Per Share

 = 

Total Cash

Average Shares

 = 
2.23 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Onconova Cash Per Share Comparison

Onconova Therapeutics is currently under evaluation in cash per share category among its peers.

Onconova Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Onconova Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Onconova Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Onconova Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Onconova Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Onconova Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.

Onconova Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Onconova Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Onconova Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Onconova Therapeutics' important profitability drivers and their relationship over time.

Use Onconova Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onconova Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onconova Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Onconova Therapeutics Pair Trading

Onconova Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Onconova Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onconova Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onconova Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onconova Therapeutics to buy it.
The correlation of Onconova Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onconova Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onconova Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onconova Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Onconova Therapeutics position

In addition to having Onconova Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Machinery Thematic Idea Now

Machinery
Machinery Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Machinery theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Machinery Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Consideration for investing in Onconova Stock

If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation